Patents by Inventor Chaofeng LONG

Chaofeng LONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250250275
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 28, 2025
    Publication date: August 7, 2025
    Inventors: Jian XIONG, Chaofeng LONG, Jingjing WANG, Xiaoxin CHEN, KEVIN X. CHEN, Cheng XIE, Peng LI, Xuanjia PENG, Jian Li, Shuhui Chen
  • Patent number: 12319692
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 19, 2023
    Date of Patent: June 3, 2025
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Patent number: 12252487
    Abstract: Disclosed are sodium salts of pyrimidine derivatives, and a series of crystal forms thereof. The series of crystal forms exhibit a good druggability, such as stability, fluidity, compressibility, etc., and provide a variety of options of APIs for subsequent drug product development.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: March 18, 2025
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Xiaoxin Chen, Chengwu Liu, Zhuowei Liu, Zhenyou Tan, Zhiqiang Liu, Zhiwei Cheng, Chaofeng Long, Jiajun Huang, Guangqiang Zhou
  • Publication number: 20240287043
    Abstract: A class of ketoamide derivatives and an application thereof are disclosed. Specifically disclosed are a compound of formula (IV) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 5, 2022
    Publication date: August 29, 2024
    Inventors: Xiaoxin CHEN, Jingjing WANG, Jianzhou HUANG, Zhuowei LIU, Chaofeng LONG, Shuhui CHEN, KEVIN X CHEN
  • Publication number: 20240270810
    Abstract: Preparation and application of a series of polypeptides, and specifically disclosed is a polypeptide having a sequence as shown in formula (II). YAibEGT FTSDY SIAibLD KIAQK AFVKW LIAGG PSSGA PPPS0??(II).
    Type: Application
    Filed: May 30, 2022
    Publication date: August 15, 2024
    Inventors: Zhigan JIANG, Xiaoxin CHEN, Zhixiang PAN, Minglu CHEN, Haiying HE, Jianzhou HUANG, Guoping HU, Zhuowei LIU, Jian LI, Chaofeng LONG, Shuhui CHEN
  • Publication number: 20230339943
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 19, 2023
    Publication date: October 26, 2023
    Inventors: Jian XIONG, Chaofeng LONG, Jingjing WANG, Xiaoxin CHEN, KEVIN X. CHEN, Cheng XIE, Peng LI, Xuanjia PENG, Jian Li, Shuhui Chen
  • Patent number: 11725009
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: August 15, 2023
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Patent number: 11535613
    Abstract: Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: December 27, 2022
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Xiaoxin Chen, Jingjing Wang, Zhuowei Liu, Kevin X Chen, Chengwu Liu, Cheng Xie, Chaofeng Long, Peng Li, Jian Li, Shuhui Chen
  • Publication number: 20220380363
    Abstract: Disclosed are sodium salts of pyrimidine derivatives, and a series of crystal forms thereof. The series of crystal forms exhibit a good druggability, such as stability, fluidity, compressibility, etc., and provide a variety of options of APIs for subsequent drug product development.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 1, 2022
    Inventors: Xiaoxin Chen, Chengwu Liu, Zhuowei Liu, Zhenyou Tan, Zhiqiang Liu, Zhiwei Cheng, Chaofeng Long, Jiajun Huang, Guangqiang Zhou
  • Patent number: 11440903
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 13, 2022
    Assignees: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng Long, Yang Zhang, Zhengxia Chen, Xiaoxin Chen, Zhuowei Liu, Meibi Dai, Zhiqiang Liu, Shuhui Chen
  • Publication number: 20220135558
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 24, 2021
    Publication date: May 5, 2022
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Patent number: 11136319
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 5, 2021
    Assignee: Guangdong Raynovent Biotech Co., Ltd.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Patent number: 11008292
    Abstract: Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 18, 2021
    Inventors: Zhengxia Chen, Chaofeng Long, Yang Zhang, Xiaoxin Chen, Yikai Wang, Meibi Dai, Zhuowei Liu, Haixia Zhao, Xing Liu, Guoping Hu, Jian Li, Shuhui Chen
  • Publication number: 20210087181
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Application
    Filed: October 30, 2018
    Publication date: March 25, 2021
    Applicants: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng LONG, Yang ZHANG, Zhengxia CHEN, Xiaoxin CHEN, Zhuowei LIU, Meibi DAI, Zhiqiang LIU, Shuhui CHEN
  • Publication number: 20210032238
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 5, 2017
    Publication date: February 4, 2021
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Publication number: 20200407354
    Abstract: Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.
    Type: Application
    Filed: March 5, 2019
    Publication date: December 31, 2020
    Inventors: Jian Xiong, Xiaoxin Chen, Jingjing Wang, Zhuowei Liu, Kevin X Chen, Chengwu Liu, Cheng Xie, Chaofeng Long, Peng Li, Jian Li, Shuhui Chen
  • Patent number: 10766862
    Abstract: Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 8, 2020
    Assignee: Guangdong Raynovent Biotech Co., Ltd.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Shuhui Chen, Jian Li
  • Patent number: 10654808
    Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 19, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Peng Li, Shuhui Chen, Guibai Liang, Cheng Xie, Zhengwei Li, Zhifei Fu, Guoping Hu, Jian Li
  • Patent number: 10618898
    Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: April 14, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Linyun Wu, Xiaoxin Chen, Peng Zhang, Xing Liu, Li Zhang, Zhuowei Liu, Shuhui Chen, Chaofeng Long
  • Patent number: RE49128
    Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: July 12, 2022
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Lingyun Wu, Chaofeng Long, Peng Zhang, Xiaoxin Chen, Li Zhang, Zhuowei Liu, Jian Li, Shuhui Chen